coteauBeta Get App

SLBT

SL Science Holding Limited
$1.15
-12.21% Oct 23 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-89%-61%-33%-5%+24%Oct 2025Oct 2026Apr 202652w low $1.15
SLBTSPY
1W
-24.8%
1M
-30.7%
3M
-63.1%
6M
-86.8%
YTD
-89.1%
1Y
-88.9%

Live chart

Loading live chart…

What they do

SL Science Holding Limited manufactures cosmetic skin care and scalp care products. The company's products include SL bio's milk-derived exosome essence, SL bio's tangerine-derived extract, and the MilkExo concentrate series. It also offers research services in armed T-cells, gamma delta T- cells, citrus reticulata (tangerine) extract, and milk-derived exosomes.

Healthcare · Biotechnology

For information only · Important disclosures

Grades vs sector

No sector grades for SLBT yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 5 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 Coteau Long Book
Not in the current book

News

More news
SL Science Presents Preclinical Data at the 85th Annual Meeting of the Japanese Cancer Association Showing γδ T Cells Target Chemotherapy-Resistant Glioblastoma
GlobeNewswire · Sep 24
SL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Company
GlobeNewswire · Sep 02
SL Science Highlights New FDA Drug Master File for GDT Cell-Derived Exosomes, Expanding the Regulatory Foundation of its Platform
GlobeNewswire · Aug 27
SL Science Holding (SLBT) Stock May Be Fully Priced Even After A 74% Fall
Simply Wall St. · Aug 18
SL Science Leadership Co-Authors Peer-Reviewed Framework for Clinical Development of γδ T Cell Therapy in Glioblastoma
GlobeNewswire · Aug 11

Key stats

Market value$644.9M
52-week range$1.15 – $14.50
Revenue growth (latest quarter vs a year ago)-7.6%
Dividend yieldNo dividend
Valuation and fundamentals

Valuation & fundamentals

No US-GAAP 10-K/10-Q financials in SEC data (foreign filers report on Form 20-F, often under IFRS).

Earnings

SLBT earningsNo upcoming date on file
Source: Yahoo Finance · refreshed 2026-10-24 03:17:02 ET
No EPS history available.

Stats refreshed 2026-10-24 03:17:02 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Free. Not investment advice. Unsubscribe anytime.

coteau

Free to use. No card, no ads, no auto-renew.

Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Beta 0.9 · Oct 21, 2026